KR20140000767A - Use of cichorium intybus extracts for preventing, treating improving muscular atrophy - Google Patents
Use of cichorium intybus extracts for preventing, treating improving muscular atrophy Download PDFInfo
- Publication number
- KR20140000767A KR20140000767A KR1020120067936A KR20120067936A KR20140000767A KR 20140000767 A KR20140000767 A KR 20140000767A KR 1020120067936 A KR1020120067936 A KR 1020120067936A KR 20120067936 A KR20120067936 A KR 20120067936A KR 20140000767 A KR20140000767 A KR 20140000767A
- Authority
- KR
- South Korea
- Prior art keywords
- muscle
- chicory
- atrophy
- extract
- preventing
- Prior art date
Links
- 235000007542 Cichorium intybus Nutrition 0.000 title claims abstract description 76
- 239000000284 extract Substances 0.000 title claims abstract description 66
- 201000000585 muscular atrophy Diseases 0.000 title claims abstract description 39
- 244000298479 Cichorium intybus Species 0.000 title abstract description 4
- 206010028289 Muscle atrophy Diseases 0.000 claims abstract description 29
- 230000020763 muscle atrophy Effects 0.000 claims abstract description 29
- 241000723343 Cichorium Species 0.000 claims description 72
- 239000000203 mixture Substances 0.000 claims description 27
- 210000003205 muscle Anatomy 0.000 claims description 27
- 235000013305 food Nutrition 0.000 claims description 26
- 239000002904 solvent Substances 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 8
- 230000006378 damage Effects 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 210000005036 nerve Anatomy 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 230000032683 aging Effects 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 3
- 230000007659 motor function Effects 0.000 claims description 2
- 235000021028 berry Nutrition 0.000 claims 2
- 230000001276 controlling effect Effects 0.000 abstract 1
- 210000000663 muscle cell Anatomy 0.000 description 20
- 230000000694 effects Effects 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 230000006907 apoptotic process Effects 0.000 description 10
- 230000017074 necrotic cell death Effects 0.000 description 9
- 230000002265 prevention Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 5
- 201000006938 muscular dystrophy Diseases 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- -1 human serum albumin) Chemical compound 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 210000000107 myocyte Anatomy 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000004420 Creatine Kinase Human genes 0.000 description 2
- 108010042126 Creatine kinase Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000029549 Muscle injury Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000001905 cichorium intybus l. root extract Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002027 Amyotrophy Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000027747 Kennedy disease Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000002948 appetite stimulant Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000020538 atrophic muscular disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- ZFXVRMSLJDYJCH-UHFFFAOYSA-N calcium magnesium Chemical compound [Mg].[Ca] ZFXVRMSLJDYJCH-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000002361 compost Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940124568 digestive agent Drugs 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000002567 electromyography Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108091005995 glycated hemoglobin Proteins 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000001964 muscle biopsy Methods 0.000 description 1
- 230000024244 muscle cell apoptotic process Effects 0.000 description 1
- 206010028320 muscle necrosis Diseases 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 238000001584 occupational therapy Methods 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001230 polyarylate Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 239000012629 purifying agent Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000004180 red 2G Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002644 respiratory therapy Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000001991 scapula Anatomy 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000009120 supportive therapy Methods 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
Description
본 발명은 치커리(Cichorium intybus) 추출물의 근육 손상 예방, 치료 또는 개선을 위한 용도에 관한 것이다.
The present invention relates to a cichorium intybus ) The use of the extract for the prevention, treatment or amelioration of muscle damage.
근위축(atrophy)은 근육을 사용하지 않음으로써 발생하는 근육 조직의 손실 또는 근육 자체의 병 또는 근육을 지배하는 신경의 손상으로 정의할 수 있다. 일반적으로 근위축의 가장 중요한 원인은 근육을 사용하지 않음으로써 생기는 무용성 위축(Disuse atrophy)이다. 즉, 사회적으로 활동 자체가 감소하는 사람의 경우 근 긴장도(muscle tone) 자체가 감소하면서 점차 근위축으로 진행하게 된다. 이에 더해 중력이 없는 곳에서 생활하는 사람의 경우 또한 칼슘과 근육 강도의 감소에 의해 근력이 저하되는 증상을 보이게 된다. Atrophy can be defined as the loss of muscle tissue that results from not using muscle or the disease of the muscle itself or damage to the nerves that control the muscle. In general, the most important cause of muscle atrophy is disuse atrophy caused by not using muscle. In other words, in the case of a socially declining activity, muscle tone itself decreases and gradually progresses to muscular atrophy. In addition, people living in places where there is no gravity will also have a drop in muscle strength due to a decrease in calcium and muscle strength.
또한, 근육 자체의 병으로 인한 근위축은 중증 근무력증(myasthenia gravis), 근이영양증(dystrophy): 진행성근이영양증, 근긴장성근이영양증, 듀센형, 베커형, 지대형, 안면견갑상완형과 근육 자체에 발생하는 염증 등이 있고, 근육을 지배하는 신경의 손상으로 인한 근위축은 척수성 근위축(spinal muscular amyotrophy): 베라드니히-호프만형, 쿠겔베르그-벨란더병, 근위축성 측삭경화증(amyotrophic lateral sclerosis, ALS): 루게릭병 및 척수구 근위축(spinobular muscular atrophy): 케네디병 등이 있다. In addition, muscle atrophy due to the disease of the muscle itself is myasthenia gravis, dystrophy: dystrophic dystrophy, myotonic dystrophy, duchenne type, Becker's type, belt type, facial scapula and inflammation of the muscle itself. Muscle atrophy due to damage to the nerves that dominate the muscles; spinal muscular amyotrophy: Berradnich-Hoffmann's type, Kugelberg-Belander's disease, amyotrophic lateral sclerosis (ALS) : Lou Gehrig's disease and spinobular muscular atrophy: Kennedy's disease.
근위축의 발생 원인은 아직 명확하게 밝혀지지 않았으며, 현재까지 근위축 발병의 주원인으로 제기된 것은 산화물질 증가에 의한 근세포 손상, 스트레스 단백질 발현 감소로 인한 근단백질 생성-재생 감소 또는 proteosomal ubiquitination 활성화에 따른 근단백질 분해 촉진 등을 들 수 있다. The cause of muscular dystrophy has not yet been elucidated, and to date, the main causes of the development of muscular dystrophy have been suggested in terms of muscle cell damage caused by increased oxide quality, decreased muscle protein production-regeneration due to decreased stress protein expression, or activation of proteosomal ubiquitination. Accelerating myoprotein degradation, and the like.
근위축은 크레아틴 키나아제(Creatine kinase: CK), 근전도검사, 근육생검, 분자생물학적 유전자검사, 세포유전학적 검사 등을 통해 진단이 이루어지며, 현재까지의 근위축에 대한 주된 치료방법은 물리치료와, 합병증 및 기형, 기능 장애 예방을 위한 작업치료, 호흡치료의 병행 그리고 추가적으로 대증요법(symptomatic treatment)과 지지요법(supportive therapy)을 시도하는 것이 유일한 대응방법이다.
Muscle atrophy is diagnosed through creatine kinase (CK), electromyography, muscle biopsy, molecular biological genetic testing, cytogenetic testing, etc. To date, the main treatment methods for muscle atrophy are physical therapy, Occupational therapy for the prevention of complications and malformations, dysfunction, combined with respiratory therapy and additional symptomatic and supportive therapy are the only responses.
현재까지의 근 질환에 대한 치료는 증상에 대한 보조적인 요법으로 근위축의 발병을 억제하거나 완치는 기대하기 어렵다. 따라서, 근위축 질환을 치료할 수 있는 새로운 물질의 개발이 필요한 실정이다. 이에, 본 발명은 근위축 예방, 치료 또는 개선을 위한 새로운 소재를 발굴하고 이의 신규 용도를 제공하고자 한다.
To date, the treatment of muscle diseases is a supplementary therapy for symptoms, and it is difficult to suppress or cure the onset of muscle atrophy. Therefore, there is a need for the development of new materials that can treat muscular dystrophy. Accordingly, the present invention seeks to discover new materials for the prevention, treatment or improvement of muscular dystrophy and to provide new uses thereof.
상기 목적 달성을 위하여, 본 발명자들은 천연물로부터 근육의 손상, 괴사 및 아폽토시스(apoptosis)를 억제하는 물질을 발굴하고자 연구를 거듭했다. 그 결과, 치커리 추출물이 산화스트레스에 의한 근세포 손상, 괴사 및 아폽토시스를 억제하여 결과적으로 근위축을 예방, 치료 또는 개선할 수 있다는 사실을 확인하였다. In order to achieve the above object, the present inventors have conducted research to find a substance that inhibits muscle damage, necrosis and apoptosis from natural products. As a result, it was confirmed that the chicory extract can inhibit myocyte damage, necrosis and apoptosis by oxidative stress and consequently prevent, treat or improve muscle atrophy.
이에, 본 발명에서는 치커리 추출물을 유효성분으로 포함하는 근위축 예방, 치료 또는 개선을 위한 의약 조성물 및 식품 조성물을 제공한다.
Accordingly, the present invention provides a pharmaceutical composition and a food composition for preventing, treating or improving muscle atrophy comprising chicory extract as an active ingredient.
이하, 본 발명의 구성을 구체적으로 설명한다.EMBODIMENT OF THE INVENTION Hereinafter, the structure of this invention is demonstrated concretely.
본 발명의 조성물에서 유효성분으로 사용하는 치커리는 국화과(菊花科 Asteraceae)에 속하는 다년생초식물로, 간장 개선과 시력 회복에 효과가 있다고 알려져 있으며, 치커리 섭취를 늘릴 경우 장내세균 중 유익한 세균으로 알려진 비피더스균(Bifidobacteria)과 락토바실러스균(Lactobacillus)의 균수가 크게 증가한다고 보고되고 있다. 또한 치커리의 이눌린을 섭취하면 사람의 대장 내 메탄가스의 생성량이 거의 없어지고 젖산과 같은 유기산의 생성량이 두 배 정도 증가한다는 사실도 보고되었다. Chicory, which is used as an active ingredient in the composition of the present invention, is a perennial herb belonging to the Asteraceae family, and is known to be effective in improving liver and restoring vision, and is known to be a beneficial bacterium among intestinal bacteria when chicory intake is increased. It is reported that the number of bacteria of Bifidobacteria and Lactobacillus increases significantly. It has also been reported that intake of chicory consumes almost no production of methane gas in the human intestine and doubles the production of organic acids such as lactic acid.
치커리를 섭취하면 장내에서 콜레스테롤의 흡수가 50% 이상 감소하는 결과가 나타나는데, 이는 치커리 추출물이 콜레스테롤의 재흡수를 방해하고 변으로 배설되게 함으로써 간장이나 혈액 내의 총 콜레스테롤 함량을 낮추는 요인으로 작용하기 때문이다. 또한 포도당의 섭취에 미치는 치커리 추출물의 영향을 조사한 결과, 평균 혈당 농도를 나타내는 지표로 사용되는 총 당화헤모글로빈의 함량이 치커리 섭취구에서 유의적으로 낮은 수준으로 나타났다. 즉, 치커리를 섭취하면 포도당 흡수를 감소시켜 당뇨의 예방이나 치료에 효과가 있음을 확인할 수 있다.Ingestion of chicory results in a 50% or more reduction in cholesterol absorption in the intestine, which acts as a factor in lowering the total cholesterol content in the liver or blood by preventing chicory extracts from re-absorbing cholesterol and excreting it into feces. . In addition, as a result of examining the effect of chicory extract on the intake of glucose, the total glycated hemoglobin content used as an indicator of the average blood glucose level was significantly lower in the chicory intake. In other words, ingesting chicory can reduce the absorption of glucose can be confirmed to be effective in the prevention or treatment of diabetes.
치커리는 오랜 역사 동안 약초로써 사용되어 왔으며, 특별히 간과 소화기능 회복에 크게 영향을 미친다고 보고 되어왔다. 치커리는 피를 맑게 하고 감정의 흥분 상태를 완화시켜주며 여러 질병에 효과적인 약초 치료제로써 사용되어 왔다. 신체내적으로 식욕상실, 황달 및 담석증에 효과가 있고, 잎은 피부 체외적으로 염증과 종창 등에 이용되며, 이뇨제로써 체내의 불필요한 수분의 배출을 촉진시켜 통풍과 류마티즘의 치료에 이용되기도 한다. 치커리의 뿌리와 잎은 현재 식욕촉진제, 담즙의 분비를 활발하게 하는 이담제, 체내의 독소와 노폐물을 없애주는 정화제, 소화제, 저혈당증 치료제 및 배변을 도와주는 완하제 등으로 사용되고 있다. 또한, 치커리는 정맥과 동맥을 통한 혈액의 흐름과 유동체간의 교환을 원활하게 만들어 혈액순환의 개선에 효과가 있는 것으로 보고되고 있다. 치커리의 뿌리는 바로 사용하거나 말려서 사용하며 의학적으로 광범위하게 사용된다. 뿌리 추출물은 실험상으로 약한 맥박수(심장박동)를 가지게 만들어 심장 질환이나 이상에 대해서 지속적으로 연구되고 있다.Chicory has been used as a herb for a long time, and has been reported to greatly affect liver and digestive function recovery. Chicory has been used as an herbal remedy for clearing blood, relieving emotional excitement, and for many diseases. It is effective for loss of appetite, jaundice and cholelithiasis in the body, and leaves are used for inflammation and swelling of the skin in vitro, and it is also used for the treatment of gout and rheumatism by promoting the discharge of unnecessary moisture in the body as a diuretic. The roots and leaves of chicory are currently used as an appetite stimulant, bile stimulant for the secretion of bile, purifying agent to remove toxins and wastes in the body, digestive agent, hypoglycaemia and laxative to help defecation. In addition, chicory has been reported to be effective in improving blood circulation by facilitating the exchange of blood flow and fluid through veins and arteries. The roots of chicory are either used directly or dried, and are widely used medically. Root extracts have been tested experimentally for heart disease and abnormalities by making them have a weak pulse rate (heart rate).
치커리는 강한 소유욕, 자기 연민 및 자기애 등 여러 가지 감정이나 마음 상태 등에 대응하여 꽃이나 식물로 질환을 치료하는 바하 플라워 요법 중에 한 종류로도 사용된다. 치커리의 줄기 추출액은 사마귀와 같은 피부질환에 사용되어 그것을 치료하거나 제거하는 역할도 한다. 독일의 약초에 관한 치료 가이드에는 치커리가 식욕부진 및 소화불량의 개선에 효과가 있다고 보고하고 있다.Chicory is also used as a kind of Baja flower therapy to treat diseases with flowers or plants in response to various emotions and heart conditions such as strong possessiveness, self-pity and narcissism. Chicory stem extract is used for skin diseases such as warts, which also heal or eliminate it. Treatment guides for German herbs report that chicory is effective in improving anorexia and indigestion.
그 외에도 치커리는 산업에 유용하게 사용될 수 있는 바이오매스 자원으로써도 잠재적인 가능성을 지니고 있다. 치커리는 다수의 이눌린을 포함하고 있어 이들은 쉽게 알코올로 전환 될 수 있다. 또한, 잎에서는 염료를 추출하기도 하며 꽃은 말려서 가루 형태로 만들어 다른 약초와 섞어 비료에 첨가해주면 박테리아의 활동을 왕성하게 하여 짧은 시간 내에 퇴비를 만드는데 사용되기도 한다. In addition, chicory has potential as a biomass resource that could be useful for the industry. Chicory contains many inulins, which can be easily converted to alcohol. In addition, the leaves are extracted with dyes, and the flowers are dried, powdered, mixed with other herbs, and added to fertilizers, which can be used to make compost in a short time.
그러나, 근위축 예방, 치료 또는 개선을 위한 용도를 위해 치커리를 사용한 예는 여태껏 보고된 바 없다. 따라서, 본 발명은 치커리의 근위축 예방, 치료 또는 개선을 위한 신규 용도를 제공하는 것을 특징으로 한다.
However, no examples of using chicory for use in the prevention, treatment or amelioration of muscular dystrophy have been reported. Accordingly, the present invention is characterized by providing novel uses for the prevention, treatment or amelioration of chicory atrophy.
본 발명의 의약 조성물 또는 식품 조성물의 유효성분으로 사용되는 치커리 추출물은 통상의 식물 추출물의 제조방법에 따라 제조된 것일 수 있다.Chicory extract used as an active ingredient of the pharmaceutical composition or the food composition of the present invention may be prepared according to a conventional method for producing a plant extract.
한 구체예에서, 치커리 추출물은 치커리의 꽃, 잎, 가지, 열매, 뿌리, 줄기, 씨 또는 이들의 혼합물을 통상의 용매로 추출한 것일 수 있다. In one embodiment, the chicory extract may be extracted from the flowers, leaves, branches, fruits, roots, stems, seeds or mixtures of chicory with a conventional solvent.
본 발명의 한 구체예에서, 상기 치커리 추출물은 치커리의 뿌리 추출물일 수 있다.In one embodiment of the invention, the chicory extract may be a root extract of chicory.
치커리 추출물의 제조를 위해 사용되는 추출용매는 이에 제한되는 것은 아니나, 물, 유기용매 또는 이들의 혼합물로부터 선택되는 용매일 수 있다. 상기 유기용매는 탄소수 1 내지 5의 알코올, 에틸아세테이트, 아세톤 등의 극성용매, 에테르, 클로로포름, 벤젠, 헥산, 디클로로메탄 등의 비극성용매 또는 이들의 혼합용매일 수 있다. 예를 들어, 상기 탄소수 1 내지 5의 알코올은 메탄올, 에탄올, 프로판올, 부탄올 및 이소프로판올 등으로부터 선택될 수 있다. The extraction solvent used for the preparation of the chicory extract may be, but is not limited to, a solvent selected from water, an organic solvent or a mixture thereof. The organic solvent may be a polar solvent such as alcohol having 1 to 5 carbon atoms, ethyl acetate, acetone, a nonpolar solvent such as ether, chloroform, benzene, hexane, dichloromethane, or a mixed solvent thereof. For example, the alcohol having 1 to 5 carbon atoms may be selected from methanol, ethanol, propanol, butanol, isopropanol and the like.
본 발명에 있어서, 치커리 추출물은 상기 추출용매를 이용하여 추출된 1차 추출물을 극성이 다른 추출용매를 이용하여 다시 분획한 분획물을 포함한다. 예를 들어, 치커리 추출물은 치커리를 탄소수 1 내지 5의 알코올로 추출한 후, 에테르, 벤젠, 헥산 등의 극성이 다른 용매로 다시 분획한 분획물일 수 있다.In the present invention, the chicory extract includes a fraction obtained by re-fractionation of the primary extract extracted using the extraction solvent using an extraction solvent having a different polarity. For example, the chicory extract may be a fraction obtained by extracting chicory with an alcohol having 1 to 5 carbon atoms and then re-dividing the chicory with a solvent having a different polarity such as ether, benzene, and hexane.
상기 분획 시 용매는 2종 이상 사용할 수 있으며, 용매의 극성에 따라 순차적으로 사용하거나 혼합하여 사용하여, 각 용매 추출물을 제조할 수 있으나, 이에 한정되지는 않는다.Two or more solvents may be used in the fractionation, and each solvent extract may be prepared using sequentially or mixed according to the polarity of the solvent, but is not limited thereto.
상기 제조된 추출물 또는 상기 분획과정을 수행하여 수득한 분획물은 이후 여과하거나 농축 또는 건조과정을 수행하여 용매를 제거할 수 있으며, 여과, 농축 및 건조를 모두 수행할 수 있다. 구체적으로 상기 여과는 여과지를 이용하거나 감압여과기를 이용할 수 있으며, 상기 농축은 감압 농축기, 일 예로 회전 증발기를 이용하여 감압 농축할 수 있으며, 상기 건조는 일 예로 동결건조법으로 수행할 수 있다. The thus-prepared extract or the fraction obtained by performing the fractionation process may be filtered, concentrated or dried to remove the solvent, and may be subjected to both filtration, concentration and drying. Specifically, the filtration can be performed using a filter paper or a vacuum filter, and the concentration can be reduced by using a vacuum concentrator, for example, a rotary evaporator. The drying can be performed by, for example, freeze drying.
본 발명의 한 구체예로서, 본 발명에 따른 근위축 예방 및 치료용 의약 조성물은 근육을 사용하지 않음으로써 발생하는 근육 조직의 손실로 인한 근위축, 근육 자체의 병으로 인한 근위축, 근육을 지배하는 신경의 손상으로 인한 근위축의 예방 및 치료에 사용할 수 있다. In one embodiment of the present invention, the pharmaceutical composition for preventing and treating muscle atrophy according to the present invention dominates muscle atrophy due to the loss of muscle tissue caused by not using the muscle, muscle atrophy due to the disease of the muscle itself, muscle It can be used for the prevention and treatment of muscular atrophy caused by nerve damage.
하기 실시예에서 확인할 수 있는 바와 같이, 치커리 추출물은 근세포 손상, 괴사 및 아폽토시스를 억제할 수 있으며, 천연 소재이기 때문에 부작용이 없고 안전성이 매우 높으므로 근위축을 안전하면서도 효과적으로 예방, 치료할 수 있다. As can be seen in the following examples, the chicory extract can suppress myocyte damage, necrosis and apoptosis, and because it is a natural material has no side effects and very high safety, it can safely and effectively prevent and treat muscle atrophy.
본 발명에 따른 의약 조성물은 의약 분야에서 통상 사용되는 담체 및 비히클을 추가로 포함할 수 있다. 구체적으로 이온 교환 수지, 알루미나, 알루미늄 스테아레이트, 레시틴, 혈청 단백질(예, 사람 혈청 알부민), 완충 물질(예, 각종 인산염, 글리신, 소르브산, 칼륨 소르베이트, 포화 식물성 지방산의 부분적인 글리세라이드 혼합물), 물, 염 또는 전해질(예, 프로타민 설페이트, 인산수소이나트륨, 인산수소캄륨, 염화나트륨 및 아연 염), 교질성 실리카, 마그네슘 트리실리케이트, 폴리비닐피롤리돈, 셀룰로즈계 기질, 폴리에틸렌 글리콜, 나트륨 카르복시메틸셀룰로즈, 폴리아릴레이트, 왁스 또는 양모지 등을 포함할 수 있으나 이에 제한되지 않는다. The pharmaceutical composition according to the present invention may further include a carrier and a vehicle commonly used in the pharmaceutical field. Particularly glyceride mixtures of ion exchange resins, alumina, aluminum stearate, lecithin, serum proteins (e.g. human serum albumin), buffer substances (e.g. various phosphates, glycine, sorbic acid, potassium sorbate, saturated vegetable fatty acids ), Water, salts or electrolytes (e.g., protamine sulfate, disodium hydrogen phosphate, hydrogen carbonate, sodium chloride and zinc salts), colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulose based substrates, polyethylene glycols, sodium carboxy Methylcellulose, polyarylate, wax or wool, and the like, but are not limited thereto.
또한, 상기 의약 조성물은 과립제, 산제, 피복정, 정제, 캡슐제, 좌제, 시럽, 즙, 현탁제, 유제, 점적제, 주사제 또는 활성 화합물의 서방출제형의 제제형태일 수 있다. 근위축 예방 및 치료를 위한 의약 조성물은 경구 또는 비경구의 여러가지 제형으로 투여될 수 있는데, 제제화할 경우에는 의약분야에서 통상 사용되는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다. The pharmaceutical compositions may also be in the form of granules, powders, coated tablets, tablets, capsules, suppositories, syrups, juices, suspensions, emulsions, drops, injectables or sustained release formulations of the active compounds. Pharmaceutical compositions for the prevention and treatment of muscular atrophy can be administered in a variety of oral or parenteral formulations, when formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, etc. commonly used in the pharmaceutical field It can be prepared using.
경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 본 발명의 약학적 조성물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트(Calcium carbonate), 수크로스(Sucrose) 또는 락토오스(Lactose), 젤라틴 등을 섞어 조제될 수 있다. 단순한 부형제 이외에 마그네슘 스티레이트 탈크 같은 윤활제들도 사용된다. 경구투여를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient in the pharmaceutical composition of the present invention, for example, starch, calcium carbonate, It may be prepared by mixing sucrose or lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate talc are also used. Liquid preparations for oral administration include suspensions, solutions, emulsions, and syrups, and various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. .
비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성용제, 현탁용제로는 프로필렌 글리콜(Propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기재로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used. As the suppository base, witepsol, macrogol, tween 61, cacao paper, laurin, glycerogelatin and the like can be used.
한편, 본 발명에 따른 의약 조성물의 투여량은 질환의 종류, 질환의 중증도, 조성물에 함유된 유효 성분 및 다른 성분의 종류 및 함량, 제형의 종류 및 환자의 연령, 체중, 일반 건강 상태, 성별 및 식이, 투여 시간, 투여 경로 및 조성물의 분비율, 치료 기간, 동시 사용되는 약물을 비롯한 다양한 인자에 따라 조절될 수 있다. 예컨대, 성인의 경우, 본 발명의 치커리 추출물은 1일 1회 내지 수회 투여시, 0.01 내지 500 mg/kg의 용량으로 투여할 수 있다. 구체적으로는 0.1 내지 200 mg/kg, 보다 구체적으로는 0.1 내지 100 mg/kg을 일일 1 내지 3회 투여할 수 있다. 이렇게 제형화 된 단위 투여형 제제는 필요에 따라 일정시간 간격으로 수회 투여할 수 있다.
On the other hand, the dosage of the pharmaceutical composition according to the present invention, the type of disease, the severity of the disease, the type and amount of the active ingredient and other ingredients contained in the composition, the type of formulation and the age, weight, general state of health, sex and It can be adjusted according to various factors including the diet, the time of administration, the route of administration and the rate of secretion of the composition, the duration of treatment, and the drugs used concurrently. For example, in adults, the chicory extract of the present invention may be administered at a dose of 0.01 to 500 mg / kg, once or several times daily. Specifically, 0.1 to 200 mg / kg, more specifically 0.1 to 100 mg / kg may be administered 1 to 3 times daily. The unit dosage form thus formulated may be administered several times at regular time intervals as needed.
본 발명은 또한 치커리 추출물을 유효성분으로 포함하는 근위축 개선용 식품 조성물에 관한 것이다.The present invention also relates to a food composition for muscular atrophy comprising chicory extract as an active ingredient.
본 발명의 한 구체예에서, 치커리 추출물을 포함한 근위축 개선용 식품 조성물은 근육 노화 억제 또는 운동기능 향상을 위해 일상적으로 섭취할 수 있는 건강기능식품으로서 사용될 수 있다. In one embodiment of the present invention, the food composition for muscle atrophy including chicory extract can be used as a health functional food that can be ingested daily to inhibit muscle aging or improve motor function.
본 명세서에서 '건강기능 식품'이란, 치커리 추출물을 음료, 차류, 향신료, 껌, 과자류 등의 식품소재에 첨가하거나, 캡슐화, 분말화, 현탁액 등으로 제조한 식품으로, 이를 섭취할 경우 건강상 특정한 효과를 가져오는 것을 의미하나, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용시 발생할 수 있는 부작용 등이 없는 장점이 있다. 이와 같이 하여 얻어지는 본 발명의 건강기능식품은, 일상적으로 섭취하는 것이 가능하기 때문에 매우 유용하다. In the present specification, 'health functional food' is a food prepared by adding chicory extract to food materials such as beverages, teas, spices, gums, confectionery, encapsulated, powdered, suspensions, etc. Means to bring the effect, unlike the general medicine has the advantage that there are no side effects that can occur when taking a long-term use of the drug as a raw material. The health functional food of the present invention thus obtained is very useful because it can be consumed on a daily basis.
또한, 본 발명의 한 구체예에서, 치커리 추출물을 포함한 근위축 개선용 식품 조성물은 우주 생활로 인한 근육 노화 억제 또는 운동기능 향상을 위해 다양한 식품에 첨가되어 제조된 우주식품으로서 사용될 수 있다. 본 명세서에서 '우주식품'이란, 우주 생활로 인해 야기될 수 있는 문제점들을 보완해 줄 수 있도록 제조된 식품으로서 치커리 추출물을 각종 식품에 첨가하여 만든 것이다. 치커리 추출물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있으며, 치커리 추출물의 혼합양은 그의 사용 목적에 따라 통상적인 방법에 따라 적합하게 결정될 수 있다. In addition, in one embodiment of the present invention, the food composition for muscle atrophy including chicory extract can be used as a space food prepared by adding to various foods for inhibiting muscle aging due to space life or improving exercise function. In the present specification, 'space food' is made by adding chicory extract to various foods as a food prepared to supplement the problems caused by space life. The chicory extract may be added as it is or used in combination with other food or food ingredients, and the mixed amount of the chicory extract may be appropriately determined according to conventional methods depending on the purpose of use thereof.
본 발명에 따른 식품 조성물은 음료류, 육류, 초코렛, 식품류, 과자류, 피자, 라면, 기타면류, 껌류, 아이스크림류, 알코올 음료류, 비타민 복합제 등의 모든 식품을 포함한다. 식품의 종류에 따라 달라 일률적으로 규정할 수 없지만, 식품 본래의 맛을 손상시키지 않는 범위에서 첨가하면 되며, 대상 식품에 대하여 통상 0.01 내지 50 중량%, 구체적으로는 0.1 내지 20 중량%의 범위이다. 또한, 과립, 정제 또는 캡슐형태의 식품의 경우에는 통상 0.1 내지 100 중량%, 구체적으로는 5 내지 100 중량%의 범위에서 첨가하면 된다.
The food composition according to the present invention includes all foods such as beverages, meat, chocolate, foods, confectionary, pizza, ramen, other noodles, gums, ice creams, alcoholic beverages, vitamin complexes and the like. Although it cannot be prescribed | regulated uniformly according to the kind of food, what is necessary is just to add in the range which does not impair the original taste of food, and it is the range of 0.01-50 weight% normally, specifically 0.1-20 weight% with respect to the target food. In the case of food in the form of granules, tablets or capsules, it is usually added in the range of 0.1 to 100% by weight, specifically 5 to 100% by weight.
치커리 추출물은 근세포 손상, 괴사 및 아폽토시스를 억제하여 근위축을 예방, 치료 또는 개선하기 위한 유효성분으로서 유용하게 사용될 수 있다.
Chicory extract can be usefully used as an active ingredient for preventing, treating or improving muscle atrophy by inhibiting myocyte damage, necrosis and apoptosis.
도 1은 H2O2로 근육세포 괴사를 유도한 근육세포에서 치커리 추출물(뿌리 추출물 및 줄기 추출물)이 근육세포의 괴사를 농도의존적으로 예방하고 회복하는 효과를 나타낸 그래프이다.
도 2는 치커리 추출물(뿌리 추출물 및 줄기 추출물)을 5, 10, 25 및 50 μg/ml을 처리한 후 근육세포에서 배양하였을 때 나타나는 세포독성을 보여주는 그래프이다.
도 3은 치커리 뿌리 추출물을 25 및 50 μg/ml을 처리한 후 근육세포에서 아폽토시스 억제효과를 보여주는 그래프이다.1 is a graph showing the effect of chicory extract (root extract and stem extract) in the concentration-dependent prevention and recovery of muscle cells necrosis in muscle cells induced muscle cell necrosis with H 2 O 2 .
Figure 2 is a graph showing the cytotoxicity when cultured in muscle cells after treatment with chicory extract (root extract and stem extract) 5, 10, 25 and 50 μg / ml.
Figure 3 is a graph showing the effect of inhibiting apoptosis in muscle cells after 25 and 50 μg / ml of chicory root extract.
본 발명은 이들의 이점 및 특징, 그리고 그것들을 달성하는 방법을 상세하게 후술되어 있는 실시예들을 참조하면 명확해질 것이다. 그러나 본 발명은 이하에서 개시되는 실시예들에 한정되는 것이 아니라 서로 다른 다양한 형태로 구현될 것이며, 단지 본 실시예들은 본 발명의 개시가 완전하도록 하고, 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에게 발명의 범주를 완전하게 알려주기 위해 제공되는 것이며, 본 발명의 청구항의 범위에 의해 정의될 뿐이다.
BRIEF DESCRIPTION OF THE DRAWINGS The present invention will become more apparent by describing in detail exemplary embodiments thereof with reference to the attached drawings, in which: FIG. The present invention may, however, be embodied in many different forms and should not be construed as being limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art. Is provided to fully convey the scope of the invention to those skilled in the art, and is defined only by the scope of the claims of the invention.
[실시예][Example]
실시예 1: 치커리 추출물의 제조Example 1: Preparation of Chicory Extract
치커리는 농촌진흥청(Rural Dvelopment Administration, RDA)의 우수농산물관리제도(Good Agricultural Practice, GAP)에 의해 재배되었으며, 2009년 충청북도 음성(GPS: E 128° 62´ N 36° 56´)에서 수확되었다. 시료의 추출은 다음과 같이 추출하였다. 치커리 뿌리 시료 50 g 및 치커리 줄기 시료 50 g에 각각 99% 에탄올 150 ml을 첨가하여 150 rpm으로 48시간 동안 반응하여 여과한 후, 감압농축하여 동결건조 한 분말을 본 실험의 시료로 사용하였다.
Chikery was cultivated by the Rural Devel- opment Administration (RDA) Good Agricultural Practice (GAP) and was harvested in Chungcheongbuk-do Voice (GPS: E 128 ° 62'N 36 ° 56 ') in 2009. Extraction of the sample was performed as follows. 50 g of chicory root sample and 50 g of chicory stem sample were added to 150 ml of 99% ethanol, respectively, and reacted for 48 hours at 150 rpm. The resulting mixture was concentrated under reduced pressure and lyophilized powder was used as a sample of this experiment.
[실험예] 생리활성 확인 실험Experimental Example Confirmation of Biological Activity
실험예 1: 근육세포배양계에서의 항산화를 통한 생존률 향상 효과Experimental Example 1: Improvement of survival rate through antioxidant in muscle cell culture system
(1) 세포배양(1) Cell culture
정상 근육세포(C2C12)를 우태아 혈청(fetal bovine serum; FBS)이 10% 함유된 DMEM배지에서 배양하였다. 즉, 75 ㎠ 플라스틱 플라스크 (Falcon Co., England)에 정상 골격근육세포를 10% FBS, 7.5% NaHCO3 150 μg/ml, 글루타민 58.4 μg/ml 및 항생제(antibiotic)/항진균제(antimycotics) 4.4 μl/ml가 함유된 DMEM 배지에서 37℃ 및 5% CO2의 조건하에서 배양하였다. 2∼3일마다 한번씩 2차 배양하여 세포주를 유지하였다.
Normal muscle cells (C 2 C 12 ) were cultured in DMEM medium containing 10% fetal bovine serum (FBS). In a 75
(2) 세포정량(2) cell quantification
세포가 자란 75 ㎠ 플라스틱 플라스크에서 배지액을 제거하고, CMF-PBS(calcium magnesium free-phosphate buffered saline, pH 7.2)로 세척한 후, 0.25% 트립신/EDTA를 처리하여 세포를 플라스크 바닥으로부터 떼어낸 후 세포 배양액으로 중화시켜서 원심분리(1200 rpm, 5min) 하였다. 남은 세포의 펠렛(pellet)에 배양액을 가한 다음, 멸균 피펫으로 반복 흡입하여 단일세포 부유액을 만든 후 광학현미경 상에서 혈구계산판(hemocytometer)을 이용하여 측정하였다.
Remove the medium solution from the grown 75
(3) H2O2로 유도된 근육 세포괴사에 대한 치커리 추출물의 농도별 효과(3) Effect of chicory extract on H 2 O 2 induced muscle cell necrosis
H2O2로 유도된 세포괴사에 대한 치커리 추출물(뿌리 추출물 및 줄기 추출물)의 농도별 효과를 관찰하기 위하여, 먼저 96웰 플레이트에 근육세포를 5×104 cells/well이 되도록 넣고 CO2 배양기에서 배양하였다. 그 다음, 치커리 추출물을 0, 5, 10, 25 및 50 μg/ml의 농도로 각각 첨가한 후, 10% FBS-DMEM 배지로 전체부피를 100 ㎕로 조절하여 37℃, 5% CO2의 조건에서 24시간 동안 배양하였다. 이 배양액에 H2O2를 1 mM 농도로 전체부피가 200 ㎕가 되게 첨가한 다음, 이를 다시 60분 동안 배양하였다. 배양 후, EzCytox kit 10 ㎕를 첨가하고, 1시간 후 흡광도를 측정하여 그 효과를 결정하였다.
In order to observe the chicory extract concentrations effect of (root extract and stem extract) for the cell death induced by H 2 O 2, placed such that the
도 1에서 볼 수 있는 바와 같이, 1 mM의 H2O2에 의해 유도된 근육세포괴사에 대한 치커리 추출물의 농도별 근육세포 생존률을 측정한 결과, 치커리 뿌리 추출물의 농도가 0 μg/ml로부터 50 μg/ml로 증가됨에 따라 농도 의존적으로 세포 생존율이 회복됨을 확인할 수 있었다. 이에 따라, 치커리 추출물에 농도 의존적으로 근육세포 괴사 예방 효과가 증가됨을 알 수 있다.
As can be seen in Figure 1, as a result of measuring the muscle cell survival rate of the chicory extract for muscle cell necrosis induced by 1 mM H 2 O 2 , the concentration of the chicory root extract is 50 from 0 μg / ml As the concentration increased to μg / ml, it was confirmed that cell viability was recovered in a concentration-dependent manner. Accordingly, it can be seen that the effect of preventing muscle cell necrosis is increased depending on the concentration of chicory extract.
(4) 세포독성 측정 (4) cytotoxicity measurement
치커리 추출물의 독성측정은 EzCytox 키트를 이용하였다. 즉, 정상 근육세포(C2C12)를 96웰 플레이트에 5×104 cells/well 되도록 분주하였다. 이를 37℃, 5% CO2 조건의 배양기에서 배양한 후, 0, 5, 10, 25, 50 μg/ml의 다양한 농도의 치커리 추출물(뿌리 추출물 및 줄기 추출물)을 첨가하여 48시간 동안 배양하였다. 세포생존율을 48 시간 동안 배양한 정상 근육세포를 대상으로 EzCytox 키트를 이용하여 치커리 추출물의 세포독성을 결정하였다.
Toxicity of chicory extract was measured using EzCytox kit. That is, normal muscle cells (C 2 C 12 ) were dispensed to 96 ×
치커리 추출물이 첨가된 배양 정상 근육세포에서 세포독성을 측정한 결과를 도 2에 나타내었다. 치커리 추출물을 첨가하지 않았을 경우는 100%의 생존율을 보였고, 치커리 추출물을 첨가한 첨가군에서는 첨가하지 않은 군과 비슷한 생존율을 보였다. 따라서, 본 실험에 사용한 치커리 추출물은 배양 근육세포에 독성을 나타내지 않음을 알 수 있다.
The results of measuring cytotoxicity in cultured normal muscle cells to which chicory extract was added are shown in FIG. 2. When chicory extract was not added, the survival rate was 100%, and in the addition group to which chicory extract was added, the survival rate was similar to that of the non-addition group. Therefore, it can be seen that the chicory extract used in this experiment does not show toxicity to cultured muscle cells.
(5) H2O2에 의한 근육세포 아폽토시스에 대한 치커리 추출물의 효과(5) Effect of chicory extract on myocyte apoptosis by H 2 O 2
H2O2의 농도별 아포토시스에 대한 치커리 추출물의 효과를 관찰하기 위하여, 먼저 커버글라스에 근육세포를 5×104 cells/well이 되도록 넣고 CO2 배양기에서 배양시킨 다음, 치커리 추출물의 농도를 25, 50 μg/ml씩 첨가한 후, 10% FBS-DMEM 배지로 37℃, 5% CO2의 조건에서 24 시간 배양하였다. 이 배양액에 H2O2를 1 mM 농도로 첨가한 다음, 이를 다시 60분 배양시킨 후, DAPI 염색한 후 그 효과를 결정하였다.
In order to observe the effect of chicory extract on apoptosis according to the concentration of H 2 O 2 , firstly put the muscle cells in the cover glass to 5 × 10 4 cells / well and incubated in a CO 2 incubator, and then the concentration of
도 3에서와 같이 H2O2에 따른 정상 근육세포의 아폽토시스를 측정한 결과, H2O2에 의해 근육세포의 아폽토시스가 유도됨을 알 수 있었다. 치커리 추출물의 근육세포 아폽토시스 예방 능력을 측정한 결과, 치커리 추출물 첨가군이 아폽토시스를 예방함을 볼 수 있다.
As a result of measuring the apoptosis of normal muscle cells according to H 2 O 2 as shown in Figure 3, it can be seen that the apoptosis of muscle cells is induced by H 2 O 2 . As a result of measuring the ability of chicory extract to prevent muscle cell apoptosis, it can be seen that the chicory extract added group prevents apoptosis.
Claims (9)
Pharmaceutical composition for preventing and treating muscle atrophy comprising chicory extract as an active ingredient.
치커리 추출물은 치커리의 꽃, 잎, 가지, 열매, 뿌리, 줄기, 씨 또는 이들의 혼합물의 추출물인 근위축 예방 및 치료용 의약 조성물.
The method of claim 1,
Chicory extract is a pharmaceutical composition for preventing and treating muscular atrophy which is an extract of chicory flowers, leaves, branches, berries, roots, stems, seeds or mixtures thereof.
치커리 추출물은 물, 유기용매 또는 이들의 혼합물로부터 선택되는 용매로 추출한 것인 근위축 예방 및 치료용 의약 조성물.
The method of claim 1,
Chicory extract is a pharmaceutical composition for preventing and treating muscular atrophy that is extracted with a solvent selected from water, organic solvents or mixtures thereof.
근위축은 근육을 사용하지 않음으로써 발생하는 근육 조직의 손실로 인한 근위축, 근육 자체의 병으로 인한 근위축 또는 근육을 지배하는 신경의 손상으로 인한 근위축인 근위축 예방 및 치료용 의약 조성물.
The method of claim 1,
Muscular atrophy is a pharmaceutical composition for preventing and treating muscular atrophy, which is muscle atrophy due to loss of muscle tissue caused by not using muscle, muscle atrophy due to a disease of the muscle itself, or muscle atrophy due to nerves that dominate the muscle.
Food composition for muscle atrophy comprising chicory extract as an active ingredient.
치커리 추출물은 치커리의 꽃, 잎, 가지, 열매, 뿌리, 줄기, 씨 또는 이들의 혼합물의 추출물인 근위축 개선용 식품 조성물.
The method of claim 5, wherein
Chicory extract is a food composition for improving muscle atrophy which is an extract of chicory flowers, leaves, branches, berries, roots, stems, seeds or mixtures thereof.
치커리 추출물은 물, 유기용매 또는 이들의 혼합물로부터 선택되는 용매로 추출한 것인 근위축 개선용 식품 조성물.
The method of claim 5, wherein
Chicory extract is a food composition for improving muscle atrophy which is extracted with a solvent selected from water, organic solvents or mixtures thereof.
근위축은 근육을 사용하지 않음으로써 발생하는 근육 조직의 손실로 인한 근위축, 근육 자체의 병으로 인한 근위축 또는 근육을 지배하는 신경의 손상으로 인한 근위축인 근위축 개선용 식품 조성물.
The method of claim 5, wherein
Muscle atrophy is a muscle composition caused by the loss of muscle tissue caused by not using the muscle, muscle atrophy due to the disease of the muscle itself or muscle atrophy due to damage to the nerves that control the muscle.
식품 조성물은 우주 생활로 인한 근육 노화 억제 또는 운동기능 향상을 위한 우주식품에 포함되는 것인 근위축 개선용 식품 조성물.The method of claim 5, wherein
Food composition is a food composition for muscle atrophy improvement that is contained in space foods for inhibiting muscle aging or motor function due to space life.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120067936A KR101385191B1 (en) | 2012-06-25 | 2012-06-25 | Use of Cichorium intybus extracts for preventing, treating improving muscular atrophy |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120067936A KR101385191B1 (en) | 2012-06-25 | 2012-06-25 | Use of Cichorium intybus extracts for preventing, treating improving muscular atrophy |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20140000767A true KR20140000767A (en) | 2014-01-06 |
KR101385191B1 KR101385191B1 (en) | 2014-04-21 |
Family
ID=50138508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120067936A KR101385191B1 (en) | 2012-06-25 | 2012-06-25 | Use of Cichorium intybus extracts for preventing, treating improving muscular atrophy |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101385191B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015156498A1 (en) * | 2014-04-10 | 2015-10-15 | 연세대학교 원주산학협력단 | Pharmaceutical composition containing oenothera odorata extract as active ingredient for preventing or treating muscle atrophy |
KR20180079174A (en) * | 2016-12-30 | 2018-07-10 | 연세대학교 산학협력단 | Composition comprising 3,5-dicaffeoylquinic acid or extract of chrysanthemum as an effective ingredient for preventing or treating of muscular disorder or improvement of muscular functions |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100382183B1 (en) * | 2001-07-26 | 2003-05-09 | 주식회사 자광 | Pharmaceutical composition for increasing the production of nitric oxide and IFN-γ, and process for the preparation thereof |
KR101258833B1 (en) * | 2010-11-04 | 2013-05-02 | 동아대학교 산학협력단 | Composition for preventing or treating fatty liver containing chicory root extract as effective components |
KR101119773B1 (en) | 2011-04-06 | 2012-03-22 | 김성훈 | Composition for prevention and treatment of obesity comprising inositol and chicory dietary fiber, and functional health food comprising the same |
-
2012
- 2012-06-25 KR KR1020120067936A patent/KR101385191B1/en active IP Right Grant
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015156498A1 (en) * | 2014-04-10 | 2015-10-15 | 연세대학교 원주산학협력단 | Pharmaceutical composition containing oenothera odorata extract as active ingredient for preventing or treating muscle atrophy |
KR20150117514A (en) | 2014-04-10 | 2015-10-20 | 연세대학교 원주산학협력단 | Pharmaceutical composition comprising Oenothera odorata extract for preventing or treating muscle atrophy in microgravity or nervous damage |
KR20180079174A (en) * | 2016-12-30 | 2018-07-10 | 연세대학교 산학협력단 | Composition comprising 3,5-dicaffeoylquinic acid or extract of chrysanthemum as an effective ingredient for preventing or treating of muscular disorder or improvement of muscular functions |
KR20190094322A (en) * | 2016-12-30 | 2019-08-13 | 연세대학교 산학협력단 | Composition comprising 3,5-dicaffeoylquinic acid or extract of chrysanthemum as an effective ingredient for preventing or treating of muscular disorder or improvement of muscular functions |
US11160840B2 (en) | 2016-12-30 | 2021-11-02 | Industry-Academic Cooperation Foundation, Yonsei University | Composition for improvement of muscle function containing 3,5-dicaffeoylquinic acid or chrysanthemum extract |
Also Published As
Publication number | Publication date |
---|---|
KR101385191B1 (en) | 2014-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Da Costa Mousinho et al. | In vitro anti-diabetic activity of Sclerocarya birrea and Ziziphus mucronata | |
KR102064651B1 (en) | Composition for preventing or improving diabetes mellitus comprising momrdica charantia (l.) extract, chrysanthemum zawadskii var. latilobum and paeonia lactiflora extract as an effective ingredient | |
KR101499457B1 (en) | Food and pharmaceutical composition for preventing or improving atrophy comprising extract of Oenothera odorata as effective component | |
TW201609123A (en) | Salacia compositions, methods of treatment by their administration, and methods of their preparation | |
WO2015190872A1 (en) | Pharmaceutical composition containing spirulina maxima extract as active ingredient for treating and preventing obesity | |
KR101385191B1 (en) | Use of Cichorium intybus extracts for preventing, treating improving muscular atrophy | |
EP2620492A1 (en) | Platelet-derived growth factor-bb production promoter, and mesenchymal stem cell production promoter, stem cell stabilizer and dermis regenerator each comprising same | |
KR20210052377A (en) | Composition for the prevention or treatment of prostate-related disease comprising Rhodiola sachalinensis root extract containing kaempferol and epicatechin gallate | |
KR20150083622A (en) | Anti-obesity composition using acanthopanax sessiliflorus and mulberry | |
US20070003685A1 (en) | Prostacyclin production-increasing agent and blood flow enhancer | |
KR20090079650A (en) | Composition Comprising the Extracts of Lysimachia clethroides for Prevention and Treatment of Cardiovascular Diseases | |
KR101349361B1 (en) | Use of Eupatorium chinensis var. simplicifolium extracts for preventing, treating improving atrophy | |
KR20180079920A (en) | Composition for preventing, improving or treating hepatic fibrosis or liver cirrhosis comprising Cuscuta Semen extract | |
KR20120021389A (en) | A composition comprising the extract of sorghum bicolor l. moench as an active ingredient for preventing and treating inflammatory disease | |
KR101249930B1 (en) | Compositions comprising extracts of Sorbus commixta and Geranium nepalense for inhibiting osteoclastogenesis and stimulating chondrogenesis | |
KR102472951B1 (en) | A composition for immune enhancement comprising narrow-leaf erecta fig extract mixture | |
KR102241169B1 (en) | Composition for prevention, improvement or treatment of liver fibrosis or cirrhosis including Allium senescens L. Extract | |
WO2015093634A1 (en) | Use of extract of cichorium intybus for preventing, treating, or alleviating muscular damage | |
JP6020155B2 (en) | Fibroblast growth promoter | |
KR101332824B1 (en) | Pharmaceutical Compositions for Preventing or Treating Arthritis Comprising Euphorbia ebracteolata Extracts | |
KR20060106065A (en) | Hepato-protective effects of angelica keiskei root extract, 4-hydroxyderricin and xanthoangelol | |
KR101062003B1 (en) | Composition for the prevention and the treament of diabetes containing Alnus firma Sieb. et Zucc extracts or compounds separated therefrom as an effective ingredient | |
KR20210028758A (en) | Phamaceutical Composition Comprising an Extract of Artemisia scoparia for Preventing or Treating Metabolic Bone Disease-induced Bone Loss | |
KR102685818B1 (en) | A composition for improving and treating metabolic syndrome-related diseases caused by endocrine disruptors comprising benicasa hispida extract | |
KR102499105B1 (en) | A composition for improving and treating metabolic syndrome-related diseases caused by endocrine disruptors comprising narrow-leaf erecta fig extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20170410 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20180409 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20190329 Year of fee payment: 6 |